Vir Biotechnology, Inc. (Nasdaq: VIR) announced that they will be providing a corporate update and reporting financial results for the first quarter ending on March 31, 2024, on May 2, 2024. The company will be hosting a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024. The corporate update and financial results will be shared through a press release after the market closes and will be accessible on the Investors section of the Vir website at www.vir.bio. Participants can join the conference call via webcast on the Events & Presentations page of Vir’s website or by dialing the U.S. toll-free number (888) 800-8770 or international +1 (646) 307-1953, Conference ID: 756877.
Vir Biotechnology, Inc., an immunology company with a focus on empowering the immune system to treat and prevent infectious diseases and other serious conditions, has developed two technology platforms to modulate the immune system based on natural immune processes. Their clinical development pipeline includes product candidates aimed at hepatitis delta and hepatitis B viruses as well as human immunodeficiency virus (HIV). Additionally, Vir has preclinical candidates targeting influenza A and B, COVID-19 (Coronavirus Disease), Respiratory Syncytial Virus/Metapneumovirus (RSV/MPV), Human Papillomavirus (HPV) among others important information for investors is routinely posted on Vir’s website.
For media inquiries contact Carly Scaduto, Senior Director of External Communication at cscaduto@vir
